Skip to main content
U.S. flag

An official website of the United States government

Milestone 9.G

Initiate studies to link peripheral blood-based molecular signatures and central imaging and CSF biomarkers.


Success Criteria

Identification of 3 peripheral blood-based molecular signatures that have a high correlation with central imaging and/or CSF biomarkers.

Summary of Key Accomplishments

Research supported by the NIA led to the discovery and ongoing standardization/validation of plasma amyloid, tau and neurofilament light chain (NfL) biomarkers, reflecting accumulation of amyloid and tau in the brain and neurodegeneration. NIA supports a growing portfolio of projects focused on using genomic technologies (transcriptomic, proteomic, metabolomic) to discover blood-based and CSF-based biomarkers that can be used for diagnostic, prognostic purposes or as biomarkers of treatment response. These include projects that are using single-cell molecular profiling technologies.

Studies supported through the Accelerating Medicines Partnership for Alzheimer’s Disease (AMP AD) have identified multiple blood and CSF metabolite-based and protein-based signatures that correlate with CNS imaging biomarkers for AD for early and advanced stages of the disease.

This information is current as of March 2022.


Research Implementation Area
Biomarkers
Timeline
2016–2020
Status
Achieved

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations

nia.nih.gov

An official website of the National Institutes of Health